Business Wire

Adtran and Sonic Fiber Internet partner to deliver 50G PON connectivity across California

1.11.2024 15:00:00 EET | Business Wire | Press release

Share

Adtran today announced its strategic collaboration with Sonic Fiber Internet to bring 50Gbit/s passive optical network (50G PON) connectivity to California. The partnership is a proactive step to ensure Sonic continues to deliver ultra-fast broadband services that meet the growing demand for higher capacity and faster speeds across the US. By leveraging Adtran’s 50G PON technology, Sonic aims to lead the industry in connectivity standards for both residential and business customers, enabling a range of applications from smart home integration and advanced entertainment streaming to frictionless remote work and high-speed business connectivity. The technology coexists with GPON and XGS-PON, providing a seamless and cost-efficient upgrade path with no service disruption, while future-proofing the network and ensuring scalability for evolving digital needs. It also supports Combo PON setups, integrating multiple generations of fiber technology to fully maximize deployment flexibility.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241101302692/en/

Adtran’s 50G PON technology will help Sonic set a new standard for ultra-fast connectivity in the US. (Photo: Business Wire)

“Our partnership with Adtran marks a major milestone in the evolution of ultra-fast connectivity in California. By developing the state’s first 50G PON network, we’re laying the foundation to meet the rapidly growing demands of emerging technologies and data-intensive applications, as well as supporting emerging standards like Wi-Fi 7, Wi-Fi 8 and beyond,” said Stephen Bradley, VP of sales and marketing at Sonic Fiber Internet. “This collaboration keeps Sonic ahead of industry trends and consumer needs, ensuring our customers always receive the fastest and most reliable internet experience available at the lowest price. It sets the stage for a new era of connectivity, empowering our customers to embrace the future with confidence.”

Adtran and Sonic are joining forces to advance state-of-the-art FTTX connectivity that delivers symmetrical speeds of 50Gbit/s, ensuring bandwidth capacity for even the most demanding applications. Adtran and Sonic’s 50G PON partnership will support targeted rollouts in high-demand areas while providing cost-effective scalability for future growth. The new technology will also help reduce operational costs and environmental impact, making it a sustainable choice for network evolution.

“With their forward-thinking approach to advancing high-speed broadband, it’s no surprise that Sonic is taking a leading role with 50G PON. Our partnership will drive future-ready infrastructure to meet both today’s and tomorrow’s connectivity demands, further strengthening Sonic’s position as a pioneer in ultra-fast, highly reliable internet services,” commented Christoph Glingener, CTO of Adtran. “By integrating with existing fiber networks, 50G PON enables incremental upgrades that minimize disruption while allowing Sonic to stay ahead of market trends. This approach supports a variety of use cases, from enhancing connectivity in homes and high-density residential areas to powering enterprise campuses and public Wi-Fi expansion. It also future-proofs the network for emerging Wi-Fi standards and smart city infrastructure, driving down costs and accelerating widespread adoption.”

For more information on Adtran and Sonic’s 50G PON plans, please register for a joint webinar to be held on November 14.

About Adtran

ADTRAN Holdings, Inc. (NASDAQ: ADTN and FSE: QH9) is the parent company of Adtran, Inc., a leading global provider of open, disaggregated networking and communications solutions that enable voice, data, video and internet communications across any network infrastructure. From the cloud edge to the subscriber edge, Adtran empowers communications service providers around the world to manage and scale services that connect people, places and things. Adtran solutions are used by service providers, private enterprises, government organizations and millions of individual users worldwide. ADTRAN Holdings, Inc. is also the largest shareholder of Adtran Networks SE, formerly ADVA Optical Networking SE. Find more at Adtran, LinkedIn and X.

Published by
ADTRAN Holdings, Inc.
www.adtran.com

View source version on businesswire.com: https://www.businesswire.com/news/home/20241101302692/en/

Contacts

For media
Gareth Spence
+44 1904 699 358
public.relations@adtran.com

For investors
Rhonda Lambert
+1 256 963 7450
investor.relations@adtran.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

www.businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Galderma Receives U.S. FDA Approval for Differin ® Epiduo ® Acne Gel Prescription-to-OTC Switch22.5.2026 19:25:00 EEST | Press release

Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) use in ages 12 years and older, marking a significant Prescription-to-OTC transition in acne care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522074280/en/ The U.S. FDA approves Differin® Epiduo® Acne Gel Prescription-to-OTC switch This milestone represents yet another example of Galderma’s unique Integrated Dermatology strategy, demonstrating how proven innovations from its Therapeutic Dermatology portfolio can further strengthen its Dermatological Skincare offerings. The Prescription‑to‑OTC transition highlights Galderma’s scale and expertise in successfully commercializing dermatology innovations across the full spectrum of acne care. With the appro

Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 17:18:00 EEST | Press release

Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522186975/en/ Adam Plich, CEO and Co-Founder of Avanzanite Bioscience. “Thalassaemia is a complex, chronic and multisystem disease characterised by anaemia, ineffective erythropoiesis and haemo

ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 15:30:00 EEST | Press release

OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future

Enhertu ® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 15:00:00 EEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority

Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 14:45:00 EEST | Press release

Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, signalling a shift in health systems from late-stage treatment to earlier intervention. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522587414/en/ Selected from 393 submissions across 68 countries, the winning teams were recognised through the inaugural ‘Future Health Challenge 2026: Building Anticipatory Health Systems through Population Sensing’, delivered by Future Health – A Global Initiative by Abu Dhabi in collaboration with MIT Solve. Health systems globally are facing rising costs and persistent delays in diagnosis, with many conditions still identified only after symptoms become severe. At the sam

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye